Gregory P. Cosgrove, MD

Associate Professor, Pulmonary Division
Associate Director, Interstitial Lung Disease Program
Medical Director, Minimally Invasive Diagnostic Center
National Jewish Health

Associate Professor
Division of Pulmonary Sciences and Critical Care Medicine
University of Colorado Denver, Colorado


CME/CE Information

Activity Title PILOT Webinar
Topic Emerging Approaches to Treatment of IPF
Target Audience Pulmonologists, primary care physicians (internists and family physicians), physician assistants and nurse practitioners who work within pulmonology and adult primary care, respiratory therapists, pharmacists, and patients
Accreditation Type CME/CE
Release Date January 2013
Expiration Date January 31, 2015 - No longer available for credit
Estimated Time to Complete Activity 60 minutes


Upon completion of the activity, participants should be able to:

  • Describe the evidence-based diagnosis and management of IPF recommended in the 2011 ATS/ERS guidelines


Gregory P. Cosgrove, MD
Associate Professor, Pulmonary Division
Associate Director, Interstitial Lung Disease Program
Medical Director, Minimally Invasive Diagnostic Center
National Jewish Health

Associate Professor
Division of Pulmonary Sciences and Critical Care Medicine
University of Colorado
Denver, Colorado


  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice, the perception of commercial bias, and whether or not the objectives were met.
  6. Your CME/CE certificate will be available for download.



This activity is sponsored by The France Foundation.



IPF is a chronic progressive disease that is increasing in prevalence. Diagnosis is difficult, beyond the expertise of any one specialty, but has been codified in recent evidence-based guidelines. The understanding of the pathophysiology of IPF has progressed over the past decade, and this knowledge is intertwined with the clinical testing of candidate drugs. Several promising clinical candidates are in phase 3 evaluation and education of health care providers will enable both clinical trial enrollment and appropriate use of emerging medications after FDA approval. International guidelines for the diagnosis and treatment of IPF have been recently published, and provide a valuable resource for providers who manage patients with ILD. This education has been planned in accordance with the need to close these educational gaps.


The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


The France Foundation designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award 0.1 CEU to pharmacists who complete the activity, complete the registration and evaluation forms, and successfully pass a posttest (75%). There is no fee to participate in this activity. This is a knowledge-based educational activity. Your CE credits will be submitted electronically to the NABP. Pharmacists or pharmacy technicians with questions regarding their NABP e-profile or CPE Monitor should refer to the FAQ section in the NABP Web site ( or contact NABP Customer Service (This email address is being protected from spambots. You need JavaScript enabled to view it.) or telephone 847-391-4406. ACPE No. 0391-0000-13-001-H04-P.


In accordance with the ACCME Standards for Commercial Support of CME, The France Foundation will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.


It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest prior to the release of this activity.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures

The following faculty has indicated he has relationships with industry to disclose relative to the content of this CME activity:

  • Gregory P. Cosgrove, MD, has served as a consultant for the Medical Advisory Board and the Pulmonary Fibrosis Foundation


The France Foundation requires CME faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.


This activity is supported by an educational grant from Boehringer Ingelheim.


The France Foundation present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and Boehringer Ingelheim assume no liability for the information herein.


Copyright © 2013 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.


The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at


If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or This email address is being protected from spambots. You need JavaScript enabled to view it..